MACI

This brand name is authorized in Estonia, Ireland, Lithuania

Active ingredients

The drug MACI contains one active pharmaceutical ingredient (API):

1 Autologous chondrocytes UNII D5P3K3V822 - AUTOLOGOUS CULTURED CHONDROCYTES

Autologous chondrocyte implantation (ACI) is based on the extraction of the patient’s own chondrocytes isolated from healthy cartilage, their culture in vitro and their subsequent implantation into the cartilage defect. The implantation suspension is cultured and implanted as three-dimensional spheroids. Read about Autologous chondrocytes

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MACI Implantation matrix	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
M09AX02		M Musculo-skeletal system → M09 Other drugs for disorders of the musculo-skeletal system → M09A Other drugs for disorders of the musculo-skeletal system → M09AX Other drugs for disorders of the musculo-skeletal system
Discover more medicines within M09AX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1619490
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1070788, 1070789